145 related articles for article (PubMed ID: 24743358)
1. [Treatment of cancer chemotherapy-associated anemia in Japan - conditions and issues].
Yoshino I
Gan To Kagaku Ryoho; 2014 Apr; 41(4):426-31. PubMed ID: 24743358
[TBL] [Abstract][Full Text] [Related]
2. Erythropoiesis-stimulating agents (ESAs): do they still have a role in chemotherapy-induced anemia (CIA)?
Bormanis J; Quirt I; Chang J; Kouroukis CT; MacDonald D; Melosky B; Verma S; Couture F
Crit Rev Oncol Hematol; 2013 Aug; 87(2):132-9. PubMed ID: 23357249
[TBL] [Abstract][Full Text] [Related]
3. Erythropoiesis-stimulating agents in cancer patients: reflections on safety.
Wauters I; Vansteenkiste J
Expert Rev Clin Pharmacol; 2011 Jul; 4(4):467-76. PubMed ID: 22114856
[TBL] [Abstract][Full Text] [Related]
4. [Questionnaire-based survey on chemotherapy-induced anemia].
Tanaka A
Gan To Kagaku Ryoho; 2014 Apr; 41(4):421-5. PubMed ID: 24743357
[TBL] [Abstract][Full Text] [Related]
5. Darbepoetin alfa in the treatment of anemia in cancer patients undergoing chemotherapy.
Wauters I; Vansteenkiste J
Expert Rev Anticancer Ther; 2012 Nov; 12(11):1383-90. PubMed ID: 23113603
[TBL] [Abstract][Full Text] [Related]
6. Chemotherapy-induced anemia: the story of darbepoetin alfa.
Vansteenkiste J; Wauters I; Elliott S; Glaspy J; Hedenus M
Curr Med Res Opin; 2013 Apr; 29(4):325-37. PubMed ID: 23323876
[TBL] [Abstract][Full Text] [Related]
7. Thrombocytosis and venous thromboembolism in cancer patients with chemotherapy induced anemia may be related to ESA induced iron restricted erythropoiesis and reversed by administration of IV iron.
Henry DH; Dahl NV; Auerbach MA
Am J Hematol; 2012 Mar; 87(3):308-10. PubMed ID: 22262486
[TBL] [Abstract][Full Text] [Related]
8. Benefits and risks of using erythropoiesis-stimulating agents (ESAs) in lung cancer patients: study-level and patient-level meta-analyses.
Vansteenkiste J; Glaspy J; Henry D; Ludwig H; Pirker R; Tomita D; Collins H; Crawford J
Lung Cancer; 2012 Jun; 76(3):478-85. PubMed ID: 22277104
[TBL] [Abstract][Full Text] [Related]
9. 2008 Japanese Society for Dialysis Therapy: guidelines for renal anemia in chronic kidney disease.
Tsubakihara Y; Nishi S; Akiba T; Hirakata H; Iseki K; Kubota M; Kuriyama S; Komatsu Y; Suzuki M; Nakai S; Hattori M; Babazono T; Hiramatsu M; Yamamoto H; Bessho M; Akizawa T
Ther Apher Dial; 2010 Jun; 14(3):240-75. PubMed ID: 20609178
[TBL] [Abstract][Full Text] [Related]
10. Adherence to guidelines for use of erythropoiesis-stimulating agents in patients with chemotherapy-induced anemia: results of a retrospective study of an electronic medical-records database in the United States, 2002-2006.
Luo W; Nordstrom BL; Fraeman K; Nordyke R; Ranganathan G; Linz HE; Winterkorn A; Stokes M; Ross SD; Knopf K
Clin Ther; 2008 Dec; 30(12):2423-35. PubMed ID: 19167601
[TBL] [Abstract][Full Text] [Related]
11. Trends in anemia treatment among patients with five non-myeloid malignancies treated with chemotherapy in a large integrated health care delivery system in California, 2000-2013.
Xu L; Xu H; Cannavale K; Sattayapiwat O; Rodriguez R; Page JH; Chao C
Support Care Cancer; 2016 Jul; 24(7):2989-98. PubMed ID: 26872791
[TBL] [Abstract][Full Text] [Related]
12. Continued challenges with the use of erythropoiesis-stimulating agents in patients with cancer: perspectives and issues on policy-guided health care.
Arbuckle RB; Griffith NL; Iacovelli LM; Johnson PE; Jorgenson JA; Kloth DD; Lucarelli CD; Muller RJ
Pharmacotherapy; 2008 May; 28(5 Pt 2):1S-15S. PubMed ID: 18447704
[TBL] [Abstract][Full Text] [Related]
13. [Treatment of chemotherapy-induced anemia].
Kadokura G; Katsumata N
Gan To Kagaku Ryoho; 2014 Apr; 41(4):416-20. PubMed ID: 24743356
[TBL] [Abstract][Full Text] [Related]
14. Blood utilization and hemoglobin levels in cancer patients after label and coverage changes for erythropoiesis-stimulating agents.
Xu H; Kaye JA; Saltus CW; Crawford J; Gasal E; Goodnough LT
Expert Rev Hematol; 2014 Oct; 7(5):617-33. PubMed ID: 25081548
[TBL] [Abstract][Full Text] [Related]
15. [Frequency of blood transfusions for anemia caused by chemotherapy in ovarian cancer patients. Thoughts about the guidelines modified in 2006 for the treatment of anemic cancer patients by the European Organisation for Research and Treatment of Cancer].
Lehoczky O; Pulay T
Orv Hetil; 2007 Nov; 148(45):2133-7. PubMed ID: 17984024
[TBL] [Abstract][Full Text] [Related]
16. Impact of limiting erythropoiesis-stimulating agent use for chemotherapy-induced anemia on the United States blood supply margin.
Vekeman F; Bookhart BK; White J; McKenzie RS; Duh MS; Piech CT; Lefebvre P
Transfusion; 2009 May; 49(5):895-902. PubMed ID: 19175548
[TBL] [Abstract][Full Text] [Related]
17. Erythropoiesis-stimulating agents: favorable safety profile when used as indicated.
Nowrousian MR; Dunst J; Vaupel P
Strahlenther Onkol; 2008 Mar; 184(3):121-36. PubMed ID: 18330508
[TBL] [Abstract][Full Text] [Related]
18. Economic evaluation of erythropoiesis-stimulating agents for anemia related to cancer.
Klarenbach S; Manns B; Reiman T; Reaume MN; Lee H; Lloyd A; Wiebe N; Hemmelgarn B; Tonelli M
Cancer; 2010 Jul; 116(13):3224-32. PubMed ID: 20564645
[TBL] [Abstract][Full Text] [Related]
19. Questionnaire-based survey on chemotherapy-induced anemia.
Tanaka A; Yoshino I; Makino S; Katsumata N; Takahashi K; Kuwano H; Maehara Y; Nishiyama M
Int J Clin Oncol; 2014; 19(3):411-20. PubMed ID: 24610155
[TBL] [Abstract][Full Text] [Related]
20. Continuing reassessment of the risks of erythropoiesis-stimulating agents in patients with cancer.
Juneja V; Keegan P; Gootenberg JE; Rothmann MD; Shen YL; Lee KY; Weiss KD; Pazdur R
Clin Cancer Res; 2008 Jun; 14(11):3242-7. PubMed ID: 18519748
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
